[Skip to Content]
[Skip to Content Landing]
Citations 0
Letters
December 11, 2002

Risks of Postmenopausal Hormone Replacement

Author Affiliations
 

Stephen J.LurieMD, PhD, Senior Editor

 

Not Available

JAMA. 2002;288(22):2821. doi:10.1001/jama.288.22.2821-JLT1211-1-8

To the Editor: Halting the WHI estrogen plus progestin trial1 under its current stopping rules is entirely justified, but abandoning it altogether may not be. It is likely that many women, despite the increased chronic disease risks demonstrated in the trial, will wish to continue with long-term HRT for its benefit to their quality of life. It is therefore worthwhile considering what could be gained by extending the trial, and how its continuation might be achieved in an ethically acceptable manner.

First Page Preview View Large
First page PDF preview
First page PDF preview
×